Cambridge Cognition Holdings plc share price, company news, analysis and interviews

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 The Company made significant progress, with strong organic revenue growth during 2022, and broadened the Company’s platform and revenue opportunities further through the acquisition of eClinicalHealth Limited in October 2022 and the acquisition of Winterlight Labs Inc, subsequent to the year end, in January 2023. Revenue growth was ahead of market expectations at 25% in 2022 with earnings in line with market expectations.  The acquisition of Clinpal

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare to commercialise the Company’s suite of leading cognitive assessment tools in China for both the pharmaceutical and healthcare markets. The strategic partnership provides Cambridge Cognition with an efficient and low risk geographic expansion whilst leveraging the Company’s recent projects to go live in an Amazon Web Service (“AWS”)

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1.1m contract with a major pharmaceutical company to provide electronic clinical outcome assessments (“eCOA”) and hardware for a rare blood disease study running over the next two years. The new contract, with an existing customer, is for a mixture of eCOA licenses, services and hardware to support an upcoming clinical trial. As a leader in digital outcome assessments, Cambridge Cognition primarily provides cognitive measures and eCOA solutions for clinical trials in central nervous systems disorders. Impressed by Cambridge Cognition’s expertise

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £2.2 million contract providing cognitive assessments and electronic diaries for a neurodegenerative disease trial.  Revenue from the contract is expected over the next two financial years. This is a follow-on sale from a £2.1 million contract announced by the Company on 2 February 2022 with the same customer.   One person develops dementia every three minutes1, making neurodegenerative diseases a key target for drug development. To develop effective treatments, sensitive and specific cognitive assessments are essential as cognitive dysfunction is a hallmark of